Trial Outcomes & Findings for Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study) (NCT NCT03188536)
NCT ID: NCT03188536
Last Updated: 2020-10-12
Results Overview
Sociodemographic variables included age(in years), sex(male or female), body mass index(BMI), residence(rural or urban), educational level(illiterate,no studies(can only read/write),primary studies,secondary studies,higher studies), work status(unemployed,active employment,temporarily/ permanently disabled, retired, other), cohabitation(lives-alone,with relatives,alone with help from a caregiver), need for financial assistance (yes/no), degree of dependence(independent,dependent:grade I-requires help to perform activities of daily living \[ADL\] at least once a day,grade II-needs help to perform ADLs 2 or 3 times a day or grade III-needs help to perform ADLs several times a day), healthy habits (high\[jogging;climbing;cycling;swimming;sports;intensive work;moving \>20 kg loads\], moderate\[walking;dancing;domestic chores;sports with children,walking house pets;general construction work;moving \<20 kg loads\] physical activity or inactive, smoking habit (yes/no), alcohol use (yes/no).
Recruitment status
COMPLETED
Target enrollment
282 participants
Primary outcome timeframe
Day 1
Results posted on
2020-10-12
Participant Flow
Participants took part in the study at 30 investigative sites in Spain from 26 July 2017 to 30 January 2019.
Participants with a diagnosis of multiple myeloma with symptomatic relapse and/or refractory disease were observed to collect the retrospective data on Day 1.
Participant milestones
| Measure |
Multiple Myeloma (MM) Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Overall Study
STARTED
|
282
|
|
Overall Study
COMPLETED
|
276
|
|
Overall Study
NOT COMPLETED
|
6
|
Reasons for withdrawal
| Measure |
Multiple Myeloma (MM) Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Overall Study
No relapse/refractoriness(last 6 months)
|
5
|
|
Overall Study
Not participated/met inclusion criteria
|
1
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Age, Continuous
|
67.4 years
STANDARD_DEVIATION 10.5 • n=276 Participants
|
|
Sex: Female, Male
Female
|
129 Participants
n=276 Participants
|
|
Sex: Female, Male
Male
|
147 Participants
n=276 Participants
|
|
Region of Enrollment
Spain
|
276 Participants
n=276 Participants
|
|
Body Mass Index (BMI)
|
27.5 Kg/m^2
STANDARD_DEVIATION 5.1 • n=276 Participants
|
PRIMARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Percentages were rounded off.
Sociodemographic variables included age(in years), sex(male or female), body mass index(BMI), residence(rural or urban), educational level(illiterate,no studies(can only read/write),primary studies,secondary studies,higher studies), work status(unemployed,active employment,temporarily/ permanently disabled, retired, other), cohabitation(lives-alone,with relatives,alone with help from a caregiver), need for financial assistance (yes/no), degree of dependence(independent,dependent:grade I-requires help to perform activities of daily living \[ADL\] at least once a day,grade II-needs help to perform ADLs 2 or 3 times a day or grade III-needs help to perform ADLs several times a day), healthy habits (high\[jogging;climbing;cycling;swimming;sports;intensive work;moving \>20 kg loads\], moderate\[walking;dancing;domestic chores;sports with children,walking house pets;general construction work;moving \<20 kg loads\] physical activity or inactive, smoking habit (yes/no), alcohol use (yes/no).
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Age, Adults (27-90 years)
|
100 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Sex, Male
|
53.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Sex, Female
|
46.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
BMI, 15 to 52 kg/m^2
|
100 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Area of Residence, Rural
|
24.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Area of Residence, Urban
|
75.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Educational level, Illiteracy
|
0.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Educational level, No Studies (just read/write)
|
10.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Educational level, Primary studies
|
43.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Educational level, Secondary studies
|
34.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Educational level, Higher studies
|
11.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Work Status, Unemployed
|
5.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Work Status, Active
|
5.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Work Status, Temporary/permanent disability
|
20.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Work Status, Retired
|
65.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Work Status, Other
|
4.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Cohabitation status, Living Alone
|
12.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Cohabitation status, Living with Relatives
|
85.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Cohabitation, Living Alone with Assistance
|
1.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Need of Financial Support, No
|
93.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Level of Dependence, Independent
|
71.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Level of Dependence, Grade I
|
14.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Level of Dependence, Grade II
|
12.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Level of Dependence, Grade III
|
1.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Physical Activity, High
|
1.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Physical Activity, Moderate
|
45.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Physical Activity, Inactive
|
52.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Current smoking habit, Yes
|
3.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Current smoking habit, No
|
96.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Alcohol Use, Yes
|
6.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Sociodemographic Variables at Diagnosis
Alcohol Use, No
|
93.5 percentage of participants
|
PRIMARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Participants are repeated for multiple CRAB signs and cytogenic abnormalities. Percentages were rounded off.
Clinical variables at Diagnosis included age,MM type(heavy/light chain/Bence-Jones protein), international staging system(ISS),disease stage(I:low risk,β2-Microglobulin\<3.5mg/L and albumin≥3.5g/dL,II:not stage I or III,III:high risk,β2-Microglobulin≥5.5mg/L),calcium,renal insufficiency,anemia or bone lesions(CRAB) signs(serum calcium\>0.25mmol/L upper limit of normal,renal failure-creatinine clearance\<40mL/min/serum creatinine\>117μmol/L, anemia:reduction of hemoglobin(Hb)\>2g/dL below lower limit of normal or Hb\<10g/dL,bone lesions 1/more osteolytic lesion,cytogenetic abnormalities(t\[4;14\],t\[11;14\],t\[14;16\],t\[14;20\],t\[6;14\],trisomies,d\[17p\],g\[1q\]/others), risk according to cytogenetic profile(standard:trisomies,t\[11;14\];t\[6;14\],intermediate:t\[4;14\],g\[1q\], high:d\[17p\],t\[14;16\],t\[14;20\],other), eastern cooperative oncology group(ECOG) status (0:fully active,1:restricted physical activity,2:ambulatory,unable to carry out any work,3:capable of limited selfcare,4:completely disabled,5:dead).
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Age, Adults (27-90 years)
|
100 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Heavy chain, IgA
|
24.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Heavy chain, IgD
|
1.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Heavy chain, IgG
|
56.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Heavy chain, IgM
|
0.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Heavy chain, No Heavy Chain
|
16.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Light Chain, No Light Chain
|
3.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Light Chain, Kappa
|
59.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Light Chain, Lambda
|
37.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
MM Type, Bence Jones Protein, Yes
|
53.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ISS Disease Stage I
|
28.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ISS Disease Stage II
|
28.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ISS Disease Stage III
|
43.1 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
CRAB Signs, None
|
12.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
CRAB Signs, Some, Increase in blood calcium levels
|
12.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
CRAB Signs, Some, Renal failure
|
18.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
CRAB Signs, Some, Anemia
|
52.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
CRAB Signs, Some, Bone lesions
|
76.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, t (4;14)
|
11.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, t (11;14)
|
14.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, t (14;16)
|
1.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, Trisomies
|
3.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, d (17p)
|
17.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, g (1q)
|
21.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Cytogenetic abnormalities, Other
|
66.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Risk, High
|
19.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Risk, Standard
|
12.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Risk, Intermediate
|
23.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
Risk, Other
|
44.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ECOG Status, 0
|
29.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ECOG Status, 1
|
41.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ECOG Status, 2
|
22.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Diagnosis
ECOG Status, 3
|
6.2 percentage of participants
|
PRIMARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Participants are repeated across multiple categories. Percentages were rounded off.
Clinical variables include date of latest symptomatic relapse and/or refractory episode, ISS disease stage, CRAB signs, other clinical variables (plasmacytomas: medullary or extramedullary, diffuse osteopenia, fractures, neurological symptoms, infections, concomitant diseases like diabetes, neuropathy, chronic obstructive pulmonary disease (COPD), cardiovascular disease, liver failure, psychiatric and/or neurological disorders, any other secondary disorders, cytogenetic abnormalities, risk according to cytogenetic profile at relapse(standard:trisomies,t\[11;14\];t\[6;14\],intermediate:t\[4;14\],g\[1q\], high:d\[17p\],t\[14;16\],t\[14;20\],other), treatment started after latest symptomatic relapse and/or refractory episode.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
DoublePI Therapy+Steroids/Alkylating Agent,>=4Line
|
6.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Relapse Within 6 Months of Last Relapse
|
61.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I
|
37.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II
|
35.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III
|
27.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None
|
25.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some-Increase in blood calcium levels
|
9.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some-Renal Failure
|
20.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some-Anemia
|
43.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some-Bone lesions
|
65.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, t(4;14)
|
11.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, t(11;14)
|
8.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, t(14;16)
|
5.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, Trisomies
|
4.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, d (17p)
|
19.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, g (1q)
|
27.96 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Cytogenetic Abnormalities, other
|
64.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Risk, High
|
38.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard
|
12.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Risk, Intermediate
|
49.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Diffuse osteopathy
|
15.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Fractures
|
15.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Neurological symptoms
|
8.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Infections
|
15.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Diabetes
|
24.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Neuropathy
|
20.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Nephropathy
|
15.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidity, COPD
|
11.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Cardiovascular disease
|
48.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Liver failure
|
1.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities,Psychiatric or Neurological Disorder
|
14.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Other secondary disorders
|
45.7 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma
|
15.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma
|
15.6 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Anti-CD38 mAb Monotherapy, Second Line
|
0.9 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Anti-CD38 mAb Monotherapy, Third Line
|
13.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Anti-CD38 mAb Monotherapy, Fourth Line or Later
|
20.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Double PI Therapy+Steroids/Alkylating Agent,2 Line
|
9.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Double PI therapy+Steroids/Alkylating Agent,3 Line
|
10.3 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous transplant, Second Line
|
2.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous transplant, Third Line
|
7.0 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous transplant, Fourth Line or Later
|
1.2 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Allogeneic transplant, Second Line
|
0.8 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Allogeneic transplant, Third Line
|
1.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Allogeneic transplant, Fourth Line or Later
|
2.4 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous or Allogeneic Transplant, Second Line
|
2.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous or Allogeneic Transplant, Third Line
|
8.5 percentage of participants
|
|
Percentage of MM Participants Categorized by Clinical Variables at Latest Symptomatic Relapse and/or Refractory Episode
Autologous or Allogeneic Transplant, >=4 Lines
|
3.5 percentage of participants
|
SECONDARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category. Percentages were rounded off.
Clinical and Sociodemographic variables categorized by treatment selection(immunomodulators\[IMiDs\],proteasome inhibitor\[PI\]+IMiDs,PI,monoclonal antibodies\[mAb\]): Age,sex(male/female),prior treatment lines(0,1,2,3 or more),prior relapses(0,1,2,3 or more),ISS disease stage(I:low risk,β2-Microglobulin\<3.5mg/L,albumin≥3.5g/dL,II:not stage I or III,III:high risk,β2-Microglobulin≥5.5mg/L),CRAB signs(serum calcium\>0.25mmol/L upper limit of normal,renal failure-creatinine clearance\<40mL/min/serum creatinine\>117μmol/L,anemia:reduction of hemoglobin(Hb)\>2g/dL below lower limit of normal or Hb\<10g/dL,bone lesions 1/more osteolytic lesion),risk according to cytogenetic profile(standard:trisomies,t\[11;14\];t\[6;14\];high:d\[17p\],t\[14;16\],t\[14;20\],other),other clinical variables:medullary/extramedullary plasmacytomas,osteopenia,fractures,neurological symptoms,infections,concomitant diseases:diabetes, neuropathy, COPD, cardiovascular disease, liver failure, psychiatric, neurological disorders.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Age, 38-85 years, IMiDs
|
100 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Age, 43-76 years, PI + IMiDs
|
100 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Age, 47-84 years, PI
|
100 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Age, 39-80 years, mAb
|
100 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Age, 53-90 years, Other
|
100 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Male, IMiDs
|
49.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Female, IMiDs
|
50.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Male, PI + IMiDs
|
61.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Female, PI + IMiDs
|
38.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Male, PI
|
47.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Female, PI
|
52.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Male, mAb
|
55.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Female, mAb
|
44.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Male, Other
|
57.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Sex, Female, Other
|
42.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 1, IMiDs
|
50.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 2, IMiDs
|
28.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 3 or more, IMiDs
|
21.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 1, PI + IMiDs
|
63.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 2, PI + IMiDs
|
16.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 3 or more, PI + IMiDs
|
20.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 1, PI
|
44.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 2, PI
|
35.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 3 or more, PI
|
20.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 1, mAb
|
26.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 2, mAb
|
29.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 3 or more, mAb
|
44.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 1, Other
|
11.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 2, Other
|
26.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Prior lines of treatment, 3 or more, Other
|
61.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 0, IMiDs
|
43.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 1, IMiDs
|
31.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 2, IMiDs
|
12.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 3 and more, IMiDs
|
12.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 0, PI + IMiDs
|
49.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 1, PI + IMiDs
|
36.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 2, PI + IMiDs
|
2.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 3 or more, PI + IMiDs
|
12.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 0, PI
|
47.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 1, PI
|
32.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 2, PI
|
2.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 3 or more, PI
|
17.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 0, mAb
|
27.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 1, mAb
|
26.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 2, mAb
|
18.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 3 or more, mAb
|
27.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 0, Other
|
11.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 1, Other
|
26.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 2, Other
|
23.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Number of prior relapses, 3 or more, Other
|
38.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I, IMiDs
|
38.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II, IMiDs
|
38.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III, IMiDs
|
23.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I, PI + IMiDs
|
51.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II, PI + IMiDs
|
28.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III, PI + IMiDs
|
20.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I, PI
|
20.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II, PI
|
54.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III, PI
|
25.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I, mAb
|
40.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II, mAb
|
32.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III, mAb
|
28.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage I, Other
|
23.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage II, Other
|
23.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
ISS Disease Stage III, Other
|
52.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None, IMiDs
|
29.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some, IMiDs
|
70.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None, PI + IMiDs
|
14.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some, PI + IMiDs
|
85.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None, PI
|
20.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some, PI
|
79.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None, mAb
|
31.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some, mAb
|
68.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, None, Other
|
23.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
CRAB Signs, Some, Other
|
76.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, None, IMiDs
|
41.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Some, IMiDs
|
58.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, None, PI + IMiDs
|
49.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Some, PI + IMiDs
|
51.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, None, PI
|
35.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Some, PI
|
64.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, None, mAb
|
32.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Some, mAb
|
67.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, None, Other
|
23.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Comorbidities, Some, Other
|
76.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, High, IMiDs
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard, IMiDs
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, High, PI + IMiDs
|
41.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard, PI + IMiDs
|
58.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, High, PI
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard, PI
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, High, mAb
|
60.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard, mAb
|
40.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, High, Other
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Risk, Standard, Other
|
50.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, Yes, IMiDs
|
15.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, No, IMiDs
|
84.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, Yes, PI + IMiDs
|
25.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, No, PI + IMiDs
|
75.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, Yes, PI
|
14.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, No, PI
|
85.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, Yes, mAb
|
8.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, No, mAb
|
91.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, Yes, Other
|
16.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Medullary Plasmacytoma, No, Other
|
84.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, Yes, IMiDs
|
12.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, No, IMiDs
|
87.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, Yes, PI + IMiDs
|
33.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, No, PI + IMiDs
|
66.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, Yes, PI
|
11.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, No, PI
|
88.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, Yes, mAb
|
6.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, No, mAb
|
93.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, Yes, Other
|
24.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Extramedullary Plasmacytoma, No, Other
|
76.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, Yes, IMiDs
|
23.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, No, IMiDs
|
76.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, Yes, PI + IMiDs
|
6.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, No, PI + IMiDs
|
93.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, Yes, PI
|
8.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, No, PI
|
91.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, Yes, mAb
|
13.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, No, mAb
|
86.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, Yes, Other
|
23.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Osteopenia, No, Other
|
76.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, Yes, IMiDs
|
15.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, No, IMiDs
|
84.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, Yes, PI + IMiDs
|
18.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, No, PI + IMiDs
|
81.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, Yes, PI
|
11.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, No, PI
|
88.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, Yes, mAb
|
14.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, No, mAb
|
85.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, Yes, Other
|
15.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Fractures, No, Other
|
84.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, Yes, IMiDs
|
10.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, No, IMiDs
|
89.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, Yes, PI + IMiDs
|
10.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, No, PI + IMiDs
|
89.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, Yes, PI
|
5.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, No, PI
|
94.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, Yes, mAb
|
1.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, No, mAb
|
98.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, Yes, Other
|
11.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Neurological Symptoms, No, Other
|
88.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, Yes, IMiDs
|
5.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, No, IMiDs
|
94.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, Yes, PI + IMiDs
|
8.2 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, No, PI + IMiDs
|
91.8 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, Yes, PI
|
5.9 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, No, PI
|
94.1 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, Yes, mAb
|
0.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, No, mAb
|
100.0 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, Yes, Other
|
7.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
MM Related Neurological Symptoms, No, Other
|
92.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, Yes, IMiDs
|
14.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, No, IMiDs
|
85.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, Yes, PI + IMiDs
|
20.4 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, No, PI + IMiDs
|
79.6 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, Yes, PI
|
14.7 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, No, PI
|
85.3 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, Yes, mAb
|
11.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, No, mAb
|
88.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, Yes, Other
|
11.5 percentage of participants
|
|
Percentage of MM Participants With Clinical and Sociodemographic Characteristics Categorized by Treatment Selection at the Latest Symptomatic Relapse and/or Refractory Episode
Infections, No, Other
|
88.5 percentage of participants
|
SECONDARY outcome
Timeframe: Day 1Population: Data was not collected for this outcome measure.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Overall number of participants analyzed are the participants with data available for analyses.
The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status/QOL scale. Most of the 30 items have 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale with a recall period of the previous week. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=273 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Health-Related Quality of Life (HRQOL) Based on European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire- Core 30
|
53.5 score on a scale
Standard Deviation 23.9
|
SECONDARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Overall number of participants analyzed are the participants with data available for analyses.
The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of previous week. Scores from each subscale were transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=273 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score
Future perspective
|
58.4 score on scale
Standard Deviation 27.7
|
|
HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score
Body image
|
72.9 score on scale
Standard Deviation 34.4
|
|
HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score
Symptoms of the disease
|
30.7 score on scale
Standard Deviation 23.2
|
|
HRQOL Based on EORTC Multiple Myeloma Module (EORTC QLQ-MY20) Subscale Score
Adverse effects of the treatment
|
25.4 score on scale
Standard Deviation 17.2
|
SECONDARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included. Number analyzed is the number of participants with data available for analyses for the specific category.
The EORTC QLQ-MY20 has 20 items across 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms, and side effects of treatment) with a recall period of previous week. Scores from each subscale were transformed from 0 to 100. For the functional scales, high scores represent improvement. For the symptom scales, higher scores represent worsening. Spanish Translated Version of EORTC Multiple Myeloma Module included 4 factors, each factor corresponds to questions related to the particular component of the scale. Factor I indicate symptoms. Factor II indicates future perspectives. Factor III indicate adverse effects of the treatment. Factor IV indicates adverse effects of the treatment and body image. Each of these factors were used for the clinical validity of the scale.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Future perspective, Factors I-II
|
60.3 score on a scale
Standard Deviation 28.2
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Future perspective, Factors III
|
53.9 score on a scale
Standard Deviation 24.9
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Body image, Factors I-II
|
73.9 score on a scale
Standard Deviation 35.5
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Body image, Factors III
|
73.0 score on a scale
Standard Deviation 32.7
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Symptoms of the disease, Factors I-II
|
31.9 score on a scale
Standard Deviation 23.6
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Symptoms of the disease, Factors III
|
27.3 score on a scale
Standard Deviation 22.1
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Adverse effects of the treatment, Factors I-II
|
24.3 score on a scale
Standard Deviation 16.9
|
|
HRQOL Based on the Spanish Translated Version of EORTC Multiple Myeloma Module (EORTC QLQ-MY20)
Adverse effects of the treatment, Factors III
|
29.0 score on a scale
Standard Deviation 17.5
|
SECONDARY outcome
Timeframe: Day 1Population: All participants eligible for analyses were included.
Healthcare resources used during medical encounters include intensive care unit (ICU) admissions, hospital admissions, visits to the emergency room, days admitted.
Outcome measures
| Measure |
Multiple Myeloma (MM) Participants
n=276 Participants
Adult participants with a diagnosis of MM received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
|
|---|---|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Consultation with the primary care physician
|
21.7 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Admitted at some healthcare service
|
56.2 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Admitted to Hospital
|
59.4 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Used ambulance to attend to the hospital
|
7.0 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Used their own transport
|
67.8 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Consultation with the oncologist
|
2.5 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Consultation with the psychologist
|
3.6 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Attended psychologist
|
60 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Attended hematologist
|
89.1 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Required some test
|
82.2 percentage of participants
|
|
Percentage of Participants With Health Care Resource Utilization (HU)
Had undergone X-ray test
|
43.2 percentage of participants
|
Adverse Events
Multiple Myeloma (MM) Participants
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
- Publication restrictions are in place
Restriction type: OTHER